VERA APARECIDA DOS SANTOS
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Cytomegalovirus infection in transplant recipients(2015) AZEVEDO, Luiz Sergio; PIERROTTI, Ligia Camera; ABDALA, Edson; COSTA, Silvia Figueiredo; STRABELLI, Tania Mara Varejao; CAMPOS, Silvia Vidal; RAMOS, Jessica Fernandes; LATIF, Acram Zahredine Abdul; LITVINOV, Nadia; MALUF, Natalya Zaidan; CAIAFFA FILHO, Helio Hehl; PANNUTI, Claudio Sergio; LOPES, Marta Heloisa; SANTOS, Vera Aparecida dos; LINARDI, Camila da Cruz Gouveia; YASUDA, Maria Aparecida Shikanai; MARQUES, Heloisa Helena de SousaCytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.
bookPart Síndrome da mononucleose infecciosa(2023) PAULA, Camila Sanson Yoshino de; MATSUO, Olivia Mari; CATHARINO, Milena Carvalho; SANTOS, Vera Aparecida dos; ALCANTARA, Flávio Ferraz de Paes e; PINTO, Maria Isabel de Moraes- Assessment of organ transplants from donors with markers of hepatitis B(2012) ABDALA, Edson; AZEVEDO, Luis Sergio Fonseca de; AVELINO-SILVA, Vivian Iida; COSTA, Silvia Figueiredo; CARAMORI, Marlova Luzzi; STRABELLI, Tania Mara Varejao; PIERROTTI, Ligia Camera; MARQUES, Heloisa Helena de Sousa; LOPES, Marta Heloisa; VARKULJA, Glaucia Fernanda; SANTOS, Vera Aparecida; SHIKANAI-YASUDA, Maria Aparecida
- Sensitivity of the Wondfo One Step COVID-19 test using serum samples(2020) SANTOS, Vera Aparecida dos; RAFAEL, Mayra Matias; SABINO, Ester Cerdeira; DUARTE, Alberto Jose da Silva
- Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients in a middle-income country(2020) COSTA, Silvia Figueiredo; BUSS, Lewis; ESPINOZA, Evelyn Patricia Sanchez; JR, Jose Mauro Vieira; SILVA, Lea Campos de Oliveira da; SOUZA, Regina Maia de; NETO, Lauro Perdigao; PORTO, Ana Paula Matos; LAZARI, Carolina; SANTOS, Vera Aparecida dos; DUARTE, Alberto da Silva; NASTRI, Ana Catharina; LEITE, Gabriel Fialkovitz da Costa; MANULI, Erika; OLIVEIRA, Maura Salaroli de; ZAMPELLI, Daniella Bosco; PASTORE JUNIOR, Laerte; SEGURADO, Aluisio Cotrim; LEVIN, Anna S.; SABINO, EsterObjectives: We evaluated a rapid chromatographic immunoassay (IgG/IgM antibodies) and an ELISA assay to diagnose COVID-19 in patient sat two Brazilian hospitals. Methods: A total of 122 subjects with COVID-19 were included: 106 SARS-COV-2 RT-PCR-positive patients and 16 RT-PCR-negative patients with symptoms and chest computed tomography (CT) consistent with COVID-19. Ninety-six historical blood donation samples were used as controls. Demographic and clinical characteristics were retrieved from electronic records. Sensitivity and specificity were calculated, as were their 95% binomial confidence intervals using the Clopper-Pearson method. All analyses were performed in R version 3.6.3. Results: The sensitivity of the chromatographic immunoassay in all RT-PCR-positive patients, irrespective of the timing of symptom onset, was 85.8% (95% binomial CI 77.7% to 91.9%). This increased with time after symptom onset, and at >14 days was 94.9% (85.9% to 98.9%). The specificity was 100% (96.4% to 100%). 15/16 (94%) RT- PCR-negative cases tested positive. The most frequent comorbidities were hypertension and diabetes mellitus and the most frequent symptoms were fever, cough, and dyspnea. All RT-PCR-negative patients had pneumonia. The most frequent thoracic CT findings were ground glass changes (n = 11, 68%), which were bilateral in 9 (56%) patients, and diffuse reticulonodular infiltrates (n = 5, 31%). Conclusions: The COVID-19 rapid chromatographic immunoassay evaluated in this study had a high sensitivity and specificity using plasma, particularly after 14 days from symptom onset. ELISA and qualitative rapid chromatographic immunoassays can be used for the diagnosis of RT-PCR-negative patients.
bookPart Infecções congênitas(2023) BAIN, Vera; BRANAS, Priscila Cristina Abduch Adas; SANTOS, Ariane Guissi dos; LAZARI, Carolina dos Santos; SANTOS, Vera Aparecida dosbookPart Doenças emergentes e reemergentes: a Covid-19 e a varíola Monkeypox(2023) PEREIRA, Maria Fernanda Bádue; SUGUITA, Priscila; LITVINOV, Nadia; SANTOS, Vera Aparecida dos; LAZARI, Carolina dos Santos; ALVARES, Paula Andrade; MIMICA, Marcelo Jenné- Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil(2020) OLIVEIRA, Luanda Mara da Silva; TIYO, Bruna Tiaki; SILVA, Lais Teodoro da; FONSECA, Luiz Augusto Marcondes; ROCHA, Rosana Coura; SANTOS, Vera Aparecida dos; CENEVIVA, Carina; BEDIN, Anderson Aparecido; ALMEIDA, Alexandre de; DUARTE, Alberto Jose da Silva; OSHIRO, Telma MiyukiCoronavirus disease 19 (COVID-19) is caused by SARS-Cov-2 and the manifestations of this infection range from an absence of symptoms all the way up to severe disease leading to death. To estimate the prevalence of past infection in a population, the most readily available method is the detection of antibodies against the virus. This study has investigated the prevalence of anti-SARS-CoV-2 antibodies in outpatients of the Hospital das Clinicas, in Sao Paulo city (Brazil), which is a large university hospital belonging to the public health system that cares for patients with complex diseases who need tertiary or quaternary medical care. Our serological inquiry was carried out for 6 weeks, with once-a-week blood sampling and included 439 patients from several outpatient services. Overall, 61 patients tested positive for anti-SARS-CoV-2 IgG (13.9%); 56.1 % of the patients live in Sao Paulo city, with the remaining living in other towns of the metropolitan area; 32.8% of the patients testing positive for IgG antibodies to SARS-CoV-2 were asymptomatic, 55.7% developed mild or moderate disease and 11.5% had to be hospitalized. The prevalence of SARS-CoV-2 positive serology was lower among patients who had received the seasonal influenza vaccine compared to the ones who did not. These findings may indicate that those individuals care more about health issues, and/or that they have a better access to health care and/or a better quality of health care service. The large proportion of patients who were unaware of having had contact with SARS-CoV-2 deserves attention, reflecting the scarcity of tests performed in the population.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence and Risk Factors Among Oligo/Asymptomatic Healthcare Workers: Estimating the Impact of Community Transmission(2021) COSTA, Silvia Figueiredo; GIAVINA-BIANCHI, Pedro; BUSS, Lewis; PERES, Carlos Henrique Mesquita; RAFAEL, Mayra Matias; SANTOS, Lanuse Garcia Neves dos; BEDIN, Anderson Aparecido; FRANCISCO, Maria Cristina Peres Braido; SATAKIE, Fatima Mitie; MENEZES, Maria Aparecida Jesus; SECCO, Ligia Maria Dal; CARON, Deyse Mayara Rodrigues; OLIVEIRA, Allan Brum de; FARIA, Matheus Finardi Lima de; PENTEADO, Angelica Sauiuri de Aurelio; SOUZA, Izabel Oliva Marcilio de; PEREIRA, Grazielly de Fatima; PEREIRA, Rafael; PORTO, Ana Paula Matos; ESPINOZA, Evelyn Patricia Sanchez; MENDES-CORREA, Maria Cassia; LAZARI, Carolina dos Santos; KALIL, Jorge; PERONDI, Maria Beatriz de Moliterno; BONFA, Eloisa Silva Dutra de Oliveira; PERREIRA, Antonio Jose; SABINO, Ester; DUARTE, Alberto Jose da Silva; SEGURADO, Aluisio Cotrim; SANTOS, Vera Aparecida dos; LEVIN, Anna S.We evaluated the seroprevalence of SARS-CoV-2 and risk factors among 4987 oligo/asymptomatic healthcare workers; seroprevalence was 14% and factors associated with SARS-CoV-2 infection were lower educational level (aOR, 1.93; 95% CI, 1.03-3.60), using public transport to work (aOR, 1.65; 95% CI, 1.07-2.62), and working in cleaning or security (aOR, 2.05; 95% CI, 1.04-4.03).